SEC Comment Letter 0000000000-23-006789 to CytoDyn Inc. (CYDY)
CytoDyn Inc.
Date: June 26, 2023 · CIK: 0001175680 · Accession: 0000000000-23-006789
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272815
Letter
United States securities and exchange commission logo June 26, 2023 Antonio Migliarese Chief Financial Officer CytoDyn Inc. 1111 Main Street, Suite 660 Vancouver, Washington 98660 Re:CytoDyn Inc. Registration Statement on Form S-1 Filed June 21, 2023 File No. 333-272815 Dear Antonio Migliarese: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mary Ann Frantz, Esq.
Show Raw Text
United States securities and exchange commission logo
June 26, 2023
Antonio Migliarese
Chief Financial Officer
CytoDyn Inc.
1111 Main Street, Suite 660
Vancouver, Washington 98660
Re:CytoDyn Inc.
Registration Statement on Form S-1
Filed June 21, 2023
File No. 333-272815
Dear Antonio Migliarese:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Mary Ann Frantz, Esq.